BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34889426)

  • 21. Distinguishing constitutional from acquired bone marrow failure in the hematology clinic.
    Groarke EM; Young NS; Calvo KR
    Best Pract Res Clin Haematol; 2021 Jun; 34(2):101275. PubMed ID: 34404527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single nucleotide polymorphism array analysis of bone marrow failure patients reveals characteristic patterns of genetic changes.
    Babushok DV; Xie HM; Roth JJ; Perdigones N; Olson TS; Cockroft JD; Gai X; Perin JC; Li Y; Paessler ME; Hakonarson H; Podsakoff GM; Mason PJ; Biegel JA; Bessler M
    Br J Haematol; 2014 Jan; 164(1):73-82. PubMed ID: 24116929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome.
    Bono E; McLornan D; Travaglino E; Gandhi S; Gallì A; Khan AA; Kulasekararaj AG; Boveri E; Raj K; Elena C; Ireland RM; Bianchessi A; Jiang J; Todisco G; Ferretti VV; Cazzola M; Marsh JCW; Malcovati L; Mufti GJ
    Leukemia; 2019 Oct; 33(10):2495-2505. PubMed ID: 30940907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significance of p53 overexpression in bone marrow biopsies from patients with bone marrow failure: aplastic anemia, hypocellular refractory anemia, and hypercellular refractory anemia.
    Elghetany MT; Vyas S; Yuoh G
    Ann Hematol; 1998 Dec; 77(6):261-4. PubMed ID: 9875662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical spectrum and clonal evolution in germline syndromes with predisposition to myeloid neoplasms.
    Perez Botero J; Ho TP; Hogan WJ; Kenderian S; Gangat N; Tefferi A; Abraham RS; Nguyen P; Oliveira JL; He R; Chen D; Viswanatha D; Rodriguez V; Khan SP; Patnaik MM
    Br J Haematol; 2018 Jul; 182(1):141-145. PubMed ID: 28485484
    [No Abstract]   [Full Text] [Related]  

  • 26. When to consider inherited marrow failure syndromes in adults.
    Gutierrez-Rodrigues F; Patel BA; Groarke EM
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):548-555. PubMed ID: 38066926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD34 and p53 immunohistochemical stains differentiate hypocellular myelodysplastic syndrome (hMDS) from aplastic anemia and a CD34 immunohistochemical stain provides useful survival information for hMDS.
    Cha CH; Park CJ; Chi HS; Seo EJ; Jang S; Cho YU; Lee KH; Lee JH; Lee JH; Im HJ; Seo JJ
    Ann Lab Med; 2014 Nov; 34(6):426-32. PubMed ID: 25368817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of clinical comprehensive genomic characterization for diagnostic categorization in patients presenting with hypocellular bone marrow failure syndromes.
    Blombery P; Fox L; Ryland GL; Thompson ER; Lickiss J; McBean M; Yerneni S; Hughes D; Greenway A; Mechinaud F; Wood EM; Lieschke GJ; Szer J; Barbaro P; Roy J; Wight J; Lynch E; Martyn M; Gaff C; Ritchie D
    Haematologica; 2021 Jan; 106(1):64-73. PubMed ID: 32054657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of immunological abnormalities of lymphocytes in bone marrow in myelodysplastic syndrome (MDS) and aplastic anemia (AA).
    Li X; Xu F; He Q; Wu L; Zhang Z; Chang C
    Intern Med; 2010; 49(14):1349-55. PubMed ID: 20647647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MDS overlap disorders and diagnostic boundaries.
    Tanaka TN; Bejar R
    Blood; 2019 Mar; 133(10):1086-1095. PubMed ID: 30670443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incorporating genetic counseling into the evaluation of pediatric bone marrow failure.
    Schneider KW; Suttman A; McKinney C; Giller R; Dollerschell K; Nakano TA
    J Genet Couns; 2022 Apr; 31(2):433-446. PubMed ID: 34570941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Border between aplastic anemia and myelodysplastic syndrome.
    Yamazaki H; Nakao S
    Int J Hematol; 2013 May; 97(5):558-63. PubMed ID: 23613266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood.
    Aalbers AM; van den Heuvel-Eibrink MM; Baumann I; Dworzak M; Hasle H; Locatelli F; De Moerloose B; Schmugge M; Mejstrikova E; Nováková M; Zecca M; Zwaan CM; Te Marvelde JG; Langerak AW; van Dongen JJ; Pieters R; Niemeyer CM; van der Velden VH
    Haematologica; 2015 Mar; 100(3):315-23. PubMed ID: 25425683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
    Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
    Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MDS-associated mutations in germline GATA2 mutated patients with hematologic manifestations.
    McReynolds LJ; Yang Y; Yuen Wong H; Tang J; Zhang Y; Mulé MP; Daub J; Palmer C; Foruraghi L; Liu Q; Zhu J; Wang W; West RR; Yohe ME; Hsu AP; Hickstein DD; Townsley DM; Holland SM; Calvo KR; Hourigan CS
    Leuk Res; 2019 Jan; 76():70-75. PubMed ID: 30578959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of germline CTC1 alterations on telomere length in acquired bone marrow failure.
    Shen W; Kerr CM; Przychozen B; Mahfouz RZ; LaFramboise T; Nagata Y; Hanna R; Radivoyevitch T; Nazha A; Sekeres MA; Maciejewski JP
    Br J Haematol; 2019 Jun; 185(5):935-939. PubMed ID: 30891747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach.
    Bennett JM; Orazi A
    Haematologica; 2009 Feb; 94(2):264-8. PubMed ID: 19144661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypocellular myelodysplastic syndromes (MDS): new proposals.
    Tuzuner N; Cox C; Rowe JM; Watrous D; Bennett JM
    Br J Haematol; 1995 Nov; 91(3):612-7. PubMed ID: 8555063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis-associated aplastic anemia presenting as a familial bone marrow failure syndrome.
    Breakey VR; Meyn S; Ng V; Allen C; Dokal I; Lansdorp PM; Abla O; Dror Y
    J Pediatr Hematol Oncol; 2009 Nov; 31(11):884-7. PubMed ID: 19779378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acquired and germline predisposition to bone marrow failure: Diagnostic features and clinical implications.
    Kallen ME; Dulau-Florea A; Wang W; Calvo KR
    Semin Hematol; 2019 Jan; 56(1):69-82. PubMed ID: 30573048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.